Apogee Therapeutics, Inc. Cash and Cash Equivalents
Apogee Therapeutics, Inc. (APGE) had Cash and Cash Equivalents of $105.57 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-10
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $105.57M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $451.80M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $131.55M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $107.91M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $105.57M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $451.80M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $131.55M 10-K · filed 2026-03-02 |
| 2025-09-30 | $107.91M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $124.19M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $106.92M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $141.79M 10-K · filed 2026-03-02 |
| 2024-09-30 | $118.78M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $307.30M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $485.46M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $118.32M 10-K · filed 2026-03-02 |
| 2023-09-30 | $188.27M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $125.07M 10-Q · filed 2024-08-12 |
| 2023-03-31 | $141.33M 10-Q · filed 2024-05-13 |
| 2022-12-31 | $151.89M 10-K · filed 2024-03-05 |